Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H (HK:1541)
HKEX:1541
Holding HK:1541?
Track your performance easily
1541 Stock Chart & Stats
Day’s RangeHK$0 - HK$0
52-Week RangeHK$3.21 - HK$30.45
Previous CloseHK$5.03
Volume10.10M
Average Volume (3M)13.11M
Market Cap
HK$2.05B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Aug 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.08
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume13,114,130
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H News
PremiumCompany Announcements
ImmuneOnco Begins Clinical Trial for Innovative NMOSD Treatment
PremiumCompany Announcements
ImmuneOnco Biopharmaceuticals Advances Lupus Treatment Trials
PremiumCompany Announcements
ImmuneOnco Raises Funds for Cancer Research
PremiumCompany Announcements
ImmuneOnco Biopharmaceuticals to Boost Capital with New Share Placement
PremiumCompany Announcements
ImmuneOnco’s IMM0306 Shows Promising Trial Results
PremiumCompany Announcements
ImmuneOnco Advances Cancer Drug Trials with Promising Results
PremiumCompany Announcements
ImmuneOnco Begins Pioneering Phase III CMML TrialPremiumCompany Announcements
ImmuneOnco Plans H Share Circulation Expansion1541 FAQ
What was ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price range in the past 12 months?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H lowest stock price was HK$3.21 and its highest was HK$30.45 in the past 12 months.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s market cap?
Currently, no data Available
When is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s upcoming earnings report date is Aug 26, 2024 which is 119 days ago.
How were ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s earnings last quarter?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H released its earnings results on Mar 25, 2024. The company reported -HK$0.602 earnings per share for the quarter, missing the consensus estimate of N/A by -HK$0.602.
Is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H overvalued?
According to Wall Street analysts ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price is currently Overvalued.
Does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H pay dividends?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H does not currently pay dividends.
What is ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H have?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H has 382,163,300 shares outstanding.
What happened to ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H’s price movement after its last earnings report?
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H reported an EPS of -HK$0.602 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.808%.
Which hedge fund is a major shareholder of ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H?
Currently, no hedge funds are holding shares in HK:1541
---
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-82.92%
12-Months-Change
Fundamentals
Return on Equity
-60.17%
Trailing 12-Months
Asset Growth
1.29%
Trailing 12-Months
Technical Analysis
Shanghai Junshi Biosciences Co., Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Kintor Pharmaceutical Ltd
―
Viva Biotech Holdings
―
---